Announcing the Binaytara Foundation 2023 Summit on Cancer Health Disparities (SCHD23)

The conference will be held at the Grand Hyatt in Seattle on April 28-30, 2023

We invite you to attend the 2023 Summit on Cancer Health Disparities (SCHD23) in Seattle, WA! This conference is one of the largest gatherings of clinicians and researchers interested in cancer health disparities. Faculty from across the country will be speaking and in attendance. Dr. David Aboulafia of Virginia Mason, Dr. Hannah Linden of Fred Hutch, and Dr. Ana Maria Lopez of Sidney Kimmel Cancer Center are the Conference Chairs, along with Associate Chairs Dr. Siddhartha Yadav of Mayo Clinic and Aparna Parikh of Massachusetts General Hospital.

SCHD23 is an accredited continuing education activity (CME activity) that will foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population. Offerings include lectures, panels, and abstract presentation sessions. Register here!

Attending SCHD23 will give you an opportunity to network with top experts and learn from their expertise, research, and experience. You don’t want to miss this dynamic meeting! Register here! Early bird registration ends on April 14, 2023. The hotel reservation deadline to receive a discounted rate is April 7. Click here to book a room. Parking is available on-site for an additional fee.

Session Agenda

The preliminary session agenda includes the following:
• Clinical trials
• Immunotherapy and cellular therapy
• Novel therapies in cancer
• Cancer care in LMIC
• Diagnostics – Pathology & Radiology
• The evolving role of machine learning in cancer care delivery
• Addressing cancer care disparities among LGBTQ, young adults, and others
• Surgical oncology services in resource-limited settings
• APP in oncology practice
• Survivorship
• Current oncology workforce – avoiding burnout and optimizing patient care
• Screening and early detection
• Abstract sessions

Call for Abstracts

We are accepting abstracts. Please visit our Abstracts page for information and to send in your research. The top three highest-scoring abstracts submitted by residents or fellows will receive complimentary registration and two free hotel nights during the conference. A resident, fellow, or trainee must be the abstract’s first author.

Conference Proceedings Publication

If you are a fellow or early career oncologist, we invite you to apply to co-author the conference proceedings publication for SCHD23. Interested in being mentored by oncologists and writing conference summaries for publication in a peer-reviewed journal? This opportunity will provide you with experience in publishing, free admission to SCHD23, and a $500 honorarium! Read the article for information and apply by emailing your CV to cme@binayfoundation.org


The Binaytara Foundation is a global cancer non-profit dedicated to improving access to cancer care in the United States and abroad through education and innovative program models that break down barriers and advance best practices in hematology and oncology. Binaytara Foundation’s major projects include hematology and oncology conferences, and the establishment of a cancer hospital in Nepal. Donate here to change lives!

 

Staff Writer - The Cancer News

Recent Posts

ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)

By: Tiantian Zhang1, Yiqun Han2, Lei Deng3 1. Department of Internal Medicine, University of Central…

7 months ago

ASCO24 LAURA Trial Summary

By: Zhiting Tang1, Lei Deng21. Unity Hospital, Rochester Regional Health, Rochester, NY2. University of Washington/Fred…

7 months ago

FDA Approves Tovorafenib for Pediatric Low-Grade Glioma With BRAF Mutation

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 29, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Lutetium Lu 177 Dotatate for SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 23, 2024, the U.S. Food and Drug…

7 months ago

FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer

By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On April 18, 2024, the U.S. Food and Drug…

7 months ago